Cannovex is a Benelux-origin biotech company which develops cannabinoid-based medicines to improve the lives of patients worldwide. Over a two year period, Cannovex has conducted an in-depth and exhaustive study of medical literature on this subject, and continues to monitor all scientific publications. These efforts establish Cannovex as the designated conversation partner, sounding board and source of information on cannabinoid medicines for all stakeholders.

Based on the insights resulting from the above-mentioned research, Cannovex is now planning the development of cannabinoid-based medicines in specific therapeutic areas and for well-defined indications. Cannovex aims to set up clinical studies, in collaboration with EU university hospitals, to provide proofs of concept (PoC). Based on these PoCs, Cannovex will explore partnerships with pharmaceutical companies to conduct end-stage clinical trials, to apply for market authorisation with European Medicines Agency (EMA) and similar authorities, and to bring our cannabinoid medicinal products to the markets worldwide.

At this stage, Cannovex has identified its first development project and has filed patents to ensure protection of the intellectual property involved. Initiation of a first Phase 1b clinical trial in association with several universitary hospitals will be initiated in the 4^th quarter of 2020 after regulatory approval. The first patient recruitment is expected in Q2 2021.

For the development of cannabinoid-based medicines, purity and exact dosing of the active pharmaceutical ingredients (APIs) is a critical success factor. Cannovex dedicates much effort to the procurement of high-purity cannabinoids that can be precisely dosed in the required formulations. These cannabinoid APIs may either be sourced from renowned international API producers and/or produced in-house. Cannovex is committed to ensure cannabinoid molecules of the highest purity, thus enabling precise dosing for each formulation.

Considering the encouraging findings of observational studies as well as the unmet medical need in specific areas, Cannovex understands the position of regulators to authorise compounded cannabinoid-products on medical prescription, while awaiting the market authorisation of cannabinoid pharmaceutical products.